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Abstract
In a growing number of laboratories the technique of
liquid chromatography-tandem mass spectrometry is
used for the quantification of cyclosporin A in whole
blood, employing cyclosporin D as the internal stan-
dard. Cyclosporin A is extensively metabolized in
vivo; in liquid chromatography-tandem mass spec-
trometry respective metabolites can give rise to both
parent and product ions that are isobaric with ions
commonly used for the detection of cyclosporin A and
cyclosporin D, respectively. In this article it is dem-
onstrated that limited chromatography with co-elu-
tion of such metabolites together with cyclosporin A
and cyclosporin D can lead to incorrect results.
Keywords: cyclosporin A; cyclosporin D; liquid chro-
matography-tandem mass spectrometry; specificity.
In tandem-mass spectrometry the detection of target
analytes is based on their physical decomposition
behavior; the molecular mass-specific selection of an
intact precursor ion of an analyte and of the respec-
tive product ion results in very high analytical speci-
ficity. This high degree of specificity can limit the
requirements of sample preparation and chromato-
graphy and may enable ‘‘high-throughput’’ routine
methods. However, the specificity of tandem-mass
spectrometry should not be assumed to be absolute
and unlimited. Given the complexity of human body
fluids as a matrix and the extensive metabolization of
certain target analytes, the specificity of liquid chro-
matography-tandem mass spectrometry (LC-MS/MS)
may be a critical issue. This is demonstrated by an
observation reported here.
With the intention of switching the quantification of
whole blood cyclosporin A (CsA) from immunoassay
technology to LC-MS/MS, we decided to modify the
LC-MS/MS method that we currently use for the quan-
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tification of sirolimus (1) by additional acquisition of
multiple reaction monitoring (MRM) mass transitions
of CsA and cyclosporin D (CsD, internal standard),
respectively (both compounds were donated by
Novartis, Grenzach-Whylen, Germany). As a modifi-
cation of our originally published method (1), extend-
ed chromatography was implemented, resulting in a
retention time of approximately 3.4 min for sirolimus
wisocratic elution after on-line solid phase extraction;
Lichrospher 100-RP-18 120=4 mm, 5 mm column
(Maisch, Ammerbuch, Germany) kept at 358C; mobile
phase 90% methanol, 10% 0.5 mM ammonium ace-
tate; flow 0.85 mL/min, post-column split 1:10x. Based
on product ion scans of CsA and CsD, respectively,
and in accordance with previously reported methods
(2–5) the following MRM mass transitions were
selected for CsA quantification: CsA, 1220™1203; and
CsD (internal standard), 1234™1217. The respective
parent ions represent the ammonium adducts of the
compounds; the product ions arise from loss of the
ammonium ion. In method validation, an inter-assay
coefficient of variation of 8.4% was found for a CsA
concentration of 67 mg/L and 5.1% for 332 mg/L
(ns21); the signal/noise ratio in a calibration sample
with a concentration of 15.6 mg/L was approximately
70. The method was linear over a calibration range
from 15.6 to 500 mg/L and no ion suppression by
matrix effects was found.
When calibration materials (obtained by spiking
hemolyzed drug-free whole blood with CsA) were
analyzed under these conditions, one single peak was
found for CsA and CsD in the respective MRM traces
(Figure 1A; retention time approx. 4.3 min for CsA,
and 4.7 min for CsD). In contrast, when whole blood
samples from CsA-treated patients were analyzed, we
noted an additional peak with a distinctly shorter
retention time of approximately 3.4 min in the MRM
traces of both CsA and CsD (Figure 1B). These early
eluting peaks probably correspond to more hydro-
philic endogenously formed metabolites of CsA shar-
ing the MRM transitions selected for the detection of
CsA and CsD. Indeed, several metabolites of CsA have
been reported that might be ionized to molecules that
are isobaric with CsA and CsD, respectively (6, 7).
Early eluting peaks were observed in all samples
from CsA-treated patients, but not in any sample from
patients receiving CsA-free immunosuppression
(n)100 each).
A quantification series of 10 samples from CsA-
treated patients was performed based on the integra-
tion of peaks with the typical retention times of
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Figure 1 Multiple reaction monitoring chromatograms of two samples analyzed for cyclosporin A by LC-MS/MS. Spiked
calibration sample (250 mg/L; A) and patient’s sample (B) applying extended chromatography (C18-RP 125=4 mm column);
identical spiked calibration sample (C) and patient’s sample (D) applying limited chromatography (C18-RP 75=3 mm column).
Cyclosporin A, mass transition 1220™1203; cyclosporin D (internal standard), mass transition 1234™1217. Y-Axis represents
relative intensity of the signal with respect to the base peak of the chromatogram. Cyclosporin A concentration of the cali-
bration sample, 250 mg/L; concentration of the patient’s sample, 107 mg/L.
CsA and CsD (4.3 and 4.7 min) that were baseline-
separated from the respective early eluting peaks;
six-point calibration with spiked whole blood as the
calibration material was performed (15.6–500 mg/L).
Close agreement between LC-MS/MS results and the
results of an immunoassay (SYVA, Dade Behring,
Marburg, Germany) was found (rs0.99; mean con-
centrations found: LC-MS/MS, 134 mg/L; immunoas-
say, 137 mg/L). As an experiment, the same series was
re-analyzed using a shorter analytical column (iden-
tical column material, 75=3 mm) but otherwise iden-
tical chromatographic and mass spectrometric
conditions, resulting in a substantially reduced ana-
lytical run time. Under these simplified chromato-
graphic conditions, CsA and CsD co-eluted with the
unspecified, more hydrophilic metabolites of CsA;
one single peak was found and integrated in both
MRM traces (Figure 1C, D), both in calibration sam-
ples and patient samples. The retention time of this
single peak was approximately 2.1 min, which is in
agreement with previously described methods for the
quantification of CsA employing CsD as the internal
standard and the same mass transitions as applied
here (2–5). The quantitative results obtained in this
series using limited chromatography differed mark-
edly from those obtained with extended chromato-
graphy and from the immunoassay results (Table 1).
The mean concentration found by the LC-MS/MS
method using limited chromatography was 58 mg/L
wPearson’s rs0.76 between CsA results obtained with
extended vs. limited chromatography; linear regres-
sion, (limited chromatography)s0.16=(extended
chromatography)q36.7 mg/Lx. In our experiment,
omission of proper chromatographic separation
resulted in a short run-time but obviously incorrect
CsA results, although identical mass spectrometric
conditions were applied.
Since ammonium adducts of both CsA and CsD
give rise to several different product ions, we tried to
find MRM transitions that might be specific for the
respective compounds, but for all transitions investi-
gated, non-compound specific peaks with different
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Table 1 Results of cyclosporin A quantification of 10
patients’ whole blood samples obtained by LC-MS/MS
applying cyclosporin D as the internal standard with different
HPLC columns and by immunoassay (Dade Behring, SYVA).
Sample Chromatography, mg/L Immunoassay,
no.
Extended Limited
mg/L
1 107 63 101
2 376 91 433
3 36 37 34
4 87 56 80
5 171 100 150
6 74 41 66
7 254 65 277
8 76 43 64
9 45 35 43
10 115 49 122
Extended chromatography, C18-RP 125=4 mm; limited chro-
matography, C18-RP 75=3 mm.
retention times were found in patient samples if
extended chromatography was applied. Our findings
were confirmed with two different LC-MS/MS systems
from the same manufacturer (Quattro LC and Quattro
Ultima Pt, Waters Micromass, Manchester, UK) but
were not tested with instruments from other
manufacturers.
Based on the protonated molecular ion of CsA
(formed with lower yield compared to the ammonium
adduct), a MRM transition of CsA was found that was
compound-specific in extended chromatography of
patient samples (1203™425; collision energy, 60 V);
this transition has been described previously (8). In
contrast, no specific MRM transition was found for
protonated CsD.
Using the specific CsA transition 1203™425 and 32-
desmethoxyrapamycin (Sigma-Aldrich, Deisenhofen,
Germany; catalogue no. D6691; transition 901™834)
as a common internal standard for both sirolimus and
CsA measurement, we found it possible to quantify
CsA under the simplified chromatographic conditions
described (75=3 mm column). This assay had a
reduced analytical run time of 3.5 min. However, coef-
ficients of variation clearly above 10% were found for
validation quality control materials. Since the reduc-
tion in the analytical run time by limited chromato-
graphy would lead to inferior analytical quality, we
finally decided to employ the method initially devel-
oped with CsD as the internal standard, extended
chromatography and a total run time of 6 min for rou-
tine CsA monitoring.
Specifically, we conclude from our observations
that CsD as an internal standard is applicable for CsA
quantification by LC-MS/MS only if extended chro-
matography is used, at least with the instruments
used in the present study. In general, we conclude –
in accordance with similar observations for the quan-
tification of mycophenolic acid by LC-MS/MS (9) –
that in analytes that undergo metabolism, non-speci-
ficity of LC-MS/MS may arise from metabolites with
identical parent and product ions as are found for the
target analytes. Therefore, careful verification of the
compound specificity of individual MRM transitions
using extended chromatography and post-dose
patient samples is mandatory for the validation of bio-
medical high-throughput LC-MS/MS methods that
typically employ minimal chromatographic
separation.
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